JP2013538566A5 - - Google Patents

Download PDF

Info

Publication number
JP2013538566A5
JP2013538566A5 JP2013523643A JP2013523643A JP2013538566A5 JP 2013538566 A5 JP2013538566 A5 JP 2013538566A5 JP 2013523643 A JP2013523643 A JP 2013523643A JP 2013523643 A JP2013523643 A JP 2013523643A JP 2013538566 A5 JP2013538566 A5 JP 2013538566A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
dom7h
acid sequence
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013523643A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013538566A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/063999 external-priority patent/WO2012020143A1/en
Publication of JP2013538566A publication Critical patent/JP2013538566A/ja
Publication of JP2013538566A5 publication Critical patent/JP2013538566A5/ja
Pending legal-status Critical Current

Links

JP2013523643A 2010-08-13 2011-08-12 改良された抗血清アルブミン結合変異体 Pending JP2013538566A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37339710P 2010-08-13 2010-08-13
US61/373,397 2010-08-13
PCT/EP2011/063999 WO2012020143A1 (en) 2010-08-13 2011-08-12 Improved anti-serum albumin binding variants

Publications (2)

Publication Number Publication Date
JP2013538566A JP2013538566A (ja) 2013-10-17
JP2013538566A5 true JP2013538566A5 (enExample) 2014-09-18

Family

ID=44582954

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013523643A Pending JP2013538566A (ja) 2010-08-13 2011-08-12 改良された抗血清アルブミン結合変異体

Country Status (4)

Country Link
US (2) US9012609B2 (enExample)
EP (1) EP2603522A1 (enExample)
JP (1) JP2013538566A (enExample)
WO (1) WO2012020143A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010092135A2 (en) 2009-02-11 2010-08-19 Novozymes Biopharma Uk Ltd. Albumin variants and conjugates
CN102741280B (zh) 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
CN106977608A (zh) 2010-04-09 2017-07-25 阿尔布麦狄克斯公司 白蛋白衍生物和变体
US9012609B2 (en) * 2010-08-13 2015-04-21 Glaxosmithkline Intellectual Property Development Limited Anti-serum albumin binding variants
HK1200842A1 (en) 2011-11-18 2015-08-14 Albumedix Ltd Proteins with improved half-life and other properties
MX2014010278A (es) 2012-03-16 2015-03-05 Novozymes Biopharma Dk As Variantes de albumina.
WO2014072481A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
WO2015036579A1 (en) * 2013-09-13 2015-03-19 Novozymes Biopharma Dk A/S Albumin variants
WO2017029407A1 (en) 2015-08-20 2017-02-23 Albumedix A/S Albumin variants and conjugates
ES2905912T3 (es) * 2015-11-13 2022-04-12 Ablynx Nv Dominios variables de inmunoglobulina de unión a albúmina sérica mejorados
JP7088911B2 (ja) 2016-05-18 2022-06-21 モデルナティエックス インコーポレイテッド リラキシンをコードするポリヌクレオチド
EP3551656A1 (en) * 2016-12-07 2019-10-16 Ablynx NV Improved serum albumin binding immunoglobulin single variable domains
DK3571224T3 (da) 2017-01-17 2024-11-11 Ablynx Nv Forbedrede serumalbuminbindere
CN117285623A (zh) 2017-01-17 2023-12-26 埃博灵克斯股份有限公司 改进的血清白蛋白结合物
PL3583125T3 (pl) 2017-02-16 2025-07-28 Sonnet BioTherapeutics, Inc. Białka fuzyjne domeny wiążącej albuminę
AR131869A1 (es) 2023-02-17 2025-05-07 Ablynx Nv POLIPÉPTIDOS QUE SE UNEN AL RECEPTOR DE Fc NEONATAL
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658739A (en) 1994-05-10 1997-08-19 The Regents Of The University Of California Method for characterization of the fine structure of protein binding sites
US6291189B1 (en) 1994-05-10 2001-09-18 Carta Proteomics, Inc. Methods for the high-resolution identification of solvent-accessible amide hydrogens in polypeptides or proteins and for characterization of the fine structure of protein binding sites
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
EP1600459A3 (en) 2002-06-28 2005-12-07 Domantis Limited Ligand
EP1578950A4 (en) 2002-10-18 2007-08-08 Univ California METHOD FOR CRYSTALLOGRAPHIC STRUCTURE DETERMINATION BY MEANS OF HYDROGEN FROM TAX ANALYSIS
PL1737962T3 (pl) 2004-03-24 2011-02-28 Domantis Ltd Uniwersalny lider GAS1
US8921528B2 (en) 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
BRPI0518761A2 (pt) 2004-12-02 2008-12-09 Domantis Ltd fusço de droga, conjugado de droga, Ácido nucleico recombinante, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir uma fusço de droga, composiÇço farmacÊutica, droga, mÉtodo de tratamento e/ou prevenÇço de uma condiÇço em um paciente, mÉtodo de retardo ou prevenÇço de progressço de doenÇa, e, mÉtodo para diminuir a absorÇço de alimentos por um paciente
WO2007085814A1 (en) 2006-01-24 2007-08-02 Domantis Limited Fusion proteins that contain natural junctions
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
AU2008259590A1 (en) 2007-06-06 2008-12-11 Domantis Limited Methods for selecting protease resistant polypeptides
EP2222709B1 (en) 2007-11-30 2016-11-23 Glaxo Group Limited Antigen-binding constructs
WO2010063818A2 (en) 2008-12-05 2010-06-10 Glaxo Group Limited Methods for selecting protease resistant polypeptides
WO2010081787A1 (en) 2009-01-14 2010-07-22 Domantis Limited IMPROVED TNFα ANTAGONISM, PROPHYLAXIS & THERAPY WITH REDUCED ORGAN NECROSIS
MX2011008752A (es) 2009-02-19 2011-09-06 Glaxo Group Ltd Variantes de union a anti-albumina de suero mejoradas.
ES2655071T3 (es) * 2009-02-19 2018-02-16 Glaxo Group Limited Variantes de unión de anti-albúmina de suero mejoradas
EP2454285A2 (en) * 2009-07-16 2012-05-23 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
SG10201406063XA (en) 2009-09-30 2014-11-27 Glaxo Group Ltd Drug fusions and conjugates with extended half life
US9012609B2 (en) * 2010-08-13 2015-04-21 Glaxosmithkline Intellectual Property Development Limited Anti-serum albumin binding variants

Similar Documents

Publication Publication Date Title
RU2577228C2 (ru) Анти-il-17-антитела, способ их получения и способ применения
JP2013529080A5 (enExample)
JP2016539096A5 (enExample)
JP2017520575A5 (enExample)
HRP20161043T1 (hr) Ljudska antitijela visokog afiniteta u odnosu na ljudski angiopoietin-2
RS66117B1 (sr) Poboljšana veziva serumskog albumina
FI2691417T4 (fi) Vasta-aineen Fc-variantteja
RS66173B1 (sr) Poboljšana veziva serumskog albumina
JP2010526028A5 (enExample)
JP2013537416A5 (enExample)
ME00519B (me) Antitijela visokog afiniteta prema humanom il-6 receptoru
RU2019123112A (ru) Анти-il-5 антитела
IL266907B1 (en) Improved serum albumin binding immunoglobulin single variable domains
CN104245736B (zh) 抗人死亡受体5胞外区的人源化单克隆抗体
JP2013519721A5 (enExample)
RU2017144098A (ru) Гетеродимеризованный полипептид
JP2016503412A5 (ja) Il−6アンタゴニストおよびその使用
IL276286B2 (en) FC variants with improved binding to FCRN and extended half-life
JP2019506841A5 (enExample)
JP2009539349A5 (enExample)
JP2009519944A5 (enExample)
JP2018509887A5 (enExample)
JP2014530001A5 (enExample)
JP2016512214A5 (enExample)
CA2930162A1 (en) Multifunctional antibodies binding to egfr and met